BioNTech and OncoC4 reported Phase III survival data for their anti‑CTLA‑4 antibody in lung cancer showing a greater than 50% reduction in risk of death in the trial population. The survival benefit prompted investor and clinical attention, but subsequent analyses highlighted a challenging tolerability profile that may complicate broader adoption. Company releases and peer coverage noted the magnitude of the survival signal alongside elevated adverse events compared with control arms. Regulators and clinicians will weigh efficacy against safety as the program advances toward potential submissions. Future steps will include detailed safety characterization, potential label strategies and discussions with regulatory agencies about benefit‑risk tradeoffs.